PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-15.30%
Cash & equivalents declining -15.30% while AXSM's grows 7.41%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-15.30%
Below half of AXSM's 7.41%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.91%
Below half of AXSM's 8.88%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-12.74%
0.75-0.9x AXSM's -14.21%. Bill Ackman questions if competitor invests more heavily in future capacity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Less than half of AXSM's 57.56%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-1.64%
Below half of AXSM's 28.89%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Below half of AXSM's 9.01%. Michael Burry sees a potential red flag for stagnation or capital shortage.
72.22%
Above 1.5x AXSM's 16.73%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.94%
Less than half of AXSM's 908.58%. David Dodd sees fewer expansions in other current obligations.
32.21%
50-75% of AXSM's 44.88%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.21%
Above 1.5x AXSM's 19.39%. Michael Burry sees a potential leverage warning sign.
0.06%
Less than half of AXSM's 7.69%. David Dodd sees fewer share issuances vs. competitor.
-3.27%
Below half AXSM's -10.74%. Michael Burry suspects major net losses or high dividends vs. competitor.
0.51%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-24.85%
Below half AXSM's -554.80%. Michael Burry sees potential underperformance in building shareholder capital.
-15.58%
Below half AXSM's -277.04%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.30%
Less than half of AXSM's -11.62%. David Dodd sees better deleveraging or stronger cash buildup than competitor.